| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.008 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.008 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.009 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.01 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.01 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |